Literature DB >> 2888021

Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22.

G A Rouleau, W Wertelecki, J L Haines, W J Hobbs, J A Trofatter, B R Seizinger, R L Martuza, D W Superneau, P M Conneally, J F Gusella.   

Abstract

Bilateral acoustic neurofibromatosis (BANF) is a severe autosomal dominant disorder involving development of multiple tumours of the nervous system including meningiomas, gliomas, neurofibromas and particularly bilateral acoustic neuromas. We have used genetic linkage analysis with DNA markers to establish that the defective gene causing BANF is on chromosome 22, and is therefore distinct from the gene for the von Recklinghausen form of neurofibromatosis, which maps to chromosome 17. Linked DNA markers will be particularly valuable in BANF, facilitating early detection of tumours and thereby permitting more effective surgical intervention. In view of the reported loss of genes on chromosome 22 in meningiomas and acoustic neuromas, the genetic localization of the primary BANF defect strongly supports the concept that the disease locus encodes a 'tumour suppressor' gene. Isolation of this gene should provide insights into the pathogenesis of acoustic neuromas and other nervous system tumours, as well as into the control of proliferation and differentiation of neural crest cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888021     DOI: 10.1038/329246a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  67 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

Review 3.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

4.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

5.  Radiological investigation of neurofibromatosis type 2.

Authors:  P Akeson; S Holtås
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

6.  Neurofibromatosis with gastrointestinal stromal tumors: insights into the association.

Authors:  Shih-Ping Cheng; Ming-Jer Huang; Tsen-Long Yang; Chin-Yuan Tzen; Chien-Liang Liu; Tsang-Pai Liu; Shu-Ching Hsiao
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

7.  Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells.

Authors:  Vitor Y R Soares; Nadia A Atai; Takeshi Fujita; Sonam Dilwali; Sarada Sivaraman; Lukas D Landegger; Fred H Hochberg; Carlos A P C Oliveira; Fayez Bahmad; Xandra O Breakefield; Konstantina M Stankovic
Journal:  Neuro Oncol       Date:  2016-05-18       Impact factor: 12.300

Review 8.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

9.  Physical location of the human immunoglobulin lambda-like genes, 14.1, 16.1, and 16.2.

Authors:  T R Bauer; H E McDermid; M L Budarf; M L Van Keuren; B B Blomberg
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 10.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.